###begin article-title 0
###xml 43 47 <span type="species:ncbi:10116">rats</span>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Novel mutations in the VKORC1 gene of wild rats and mice - a response to 50 years of selection pressure by warfarin?
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Coumarin derivatives have been in world-wide use for rodent pest control for more than 50 years. Due to their retarded action as inhibitors of blood coagulation by repression of the vitamin K reductase (VKOR) activity, they are the rodenticides of choice against several species. Resistance to these compounds has been reported for rodent populations from many countries around the world and poses a considerable problem for efficacy of pest control.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 459 468 459 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 74 78 <span type="species:ncbi:10116">rats</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
In the present study, we have sequenced the VKORC1 genes of more than 250 rats and mice trapped in anticoagulant-exposed areas from four continents, and identified 18 novel and five published missense mutations, as well as eight neutral sequence variants, in a total of 178 animals. Mutagenesis in VKORC1 cDNA constructs and their recombinant expression revealed that these mutations reduced VKOR activities as compared to the wild-type protein. However, the in vitro enzyme assay used was not suited to convincingly demonstrate the warfarin resistance of all mutant proteins
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 205 213 205 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Our results corroborate the VKORC1 gene as the main target for spontaneous mutations conferring warfarin resistance. The mechanism(s) of how mutations in the VKORC1 gene mediate insensitivity to coumarins in vivo has still to be elucidated.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 830 831 826 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1043 1044 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1045 1046 1041 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 164 170 <span type="species:ncbi:9606">humans</span>
Coumarin derivatives, e.g. warfarin, act as vitamin K-antagonists and are in world-wide use as anticoagulants for therapy and prophylaxis of thrombotic diseases in humans, and as rodenticides for pest control. The physiological target of coumarins is the endoplasmic enzyme vitamin K-epoxide reductase (VKOR) [1,2]. A key component of the VKOR was recently identified and named VKORC1 [3,4]. Mutations in VKORC1 have been shown to cause two different hereditary phenotypes: warfarin-resistance (OMIM #122700) and defective blood coagulation owing to vitamin K-dependent coagulation factor deficiency type 2 (VKCFD2; OMIM #607473) [3]. The vitamin K-cycle provides vitamin K-hydroquinone, the essential cofactor for the gamma-glutamyl carboxylase catalysing the post-translational modification of the vitamin K-dependent proteins [5]. These proteins are involved in blood coagulation (factor II, VII, IX, X, Protein S, C and Z), cell cycle regulation (growth-arrest specific protein 6) and bone metabolism (osteocalcin and matrix gla-protein) [6,7]. Coumarins inhibit blood coagulation by suppressing VKOR activity and consequently gamma-carboxylation of vitamin K-dependent proteins.
###end p 9
###begin p 10
###xml 159 177 159 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 159 176 <span type="species:ncbi:10116">Rattus norvegicus</span>
Warfarin is a first-generation anticoagulant and has been used for pest control since the 1950's. Resistance to this coumarin derivative was first observed in Rattus norvegicus in the UK in 1958 [8] and led to the development of a more potent "second-generation" of anticoagulants such as difenacoum, bromadiolone and brodifacoum in the 1970's and 1980's. But soon after their introduction, resistance to specific second generation compounds was also observed in rodents [9-13].
###end p 10
###begin p 11
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 110 113 <span type="species:ncbi:10116">rat</span>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 449 454 <span type="species:ncbi:9606">human</span>
In a previous publication, we have reported on a series of mutations in the VKORC1 gene in warfarin resistant rat and mouse populations from different areas in Europe [14]. This report is an update of the mutation study presenting novel mutations and common polymorphisms found in rodents from anticoagulant-exposed areas in Europe, South Africa, East Asia and both North and South America. The different mutations were recombinantly expressed in a human cell line and their VKOR activities and inhibition by warfarin were studied.
###end p 11
###begin title 12
Results and Discussion
###end title 12
###begin p 13
###xml 392 399 392 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 14 18 <span type="species:ncbi:10116">rats</span>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
More than 250 rats and mice from anticoagulant-exposed areas in Europe, East Asia, South Africa and both North and South America were screened for mutations in the VKORC1 gene. Pre-screening by ARMS-PCR for the Tyr139Cys mutation and subsequent sequence analysis of all three exons and flanking intronic regions revealed a panel of mutations and SNPs (single nucleotide polymorphisms) in the VKORC1 gene (Tables 1 and 2). Most of these mutations have not been described before.
###end p 13
###begin p 14
###xml 44 62 44 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 44 61 <span type="species:ncbi:10116">Rattus norvegicus</span>
VKORC1 mutations and polymorphisms found in Rattus norvegicus from different geographic areas.
###end p 14
###begin p 15
###xml 44 57 44 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus </italic>
###xml 44 56 <span type="species:ncbi:10090">Mus musculus</span>
VKORC1 mutations and polymorphisms found in Mus musculus from different geographic areas in Germany and from Terceira, Azores.
###end p 15
###begin p 16
###xml 113 122 113 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
A recombinant expression system in HEK293 cells was used to assay for the VKOR activities of the mutant proteins in vitro and to study their sensitivity to warfarin (Fig. 1 and 2). Transfection efficiency was checked by Western blotting using the anti-FLAG antibody M2 and was found to be similar for all VKORC1 protein variants (data not shown).
###end p 16
###begin p 17
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative VKOR activities of different rat VKORC1 variants after recombinant expression in HEK293 cells</bold>
###xml 38 41 <span type="species:ncbi:10116">rat</span>
###xml 307 310 <span type="species:ncbi:10116">rat</span>
Relative VKOR activities of different rat VKORC1 variants after recombinant expression in HEK293 cells. Light grey bars indicate basal VKOR activities of the variants in the absence of warfarin; dark grey bars show VKOR activities after addition of 60 muM warfarin. The specific activity of the recombinant rat wild-type enzyme (WT) was 1.0 +/- 0.37 nmoles/mg protein x h and was set to 100% for comparison. Standard deviations are indicated by black error bars.
###end p 17
###begin p 18
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relative VKOR activities of different mouse VKORC1 variants after recombinant expression in HEK293 cells</bold>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
###xml 147 153 <span type="species:ncbi:10090">murine</span>
Relative VKOR activities of different mouse VKORC1 variants after recombinant expression in HEK293 cells. The specific activity of the recombinant murine wild-type enzyme was 0.65 +/- 0.15 nmoles/mg protein x h. This value was set to 100% for comparison. For further details see legend to Figure 1.
###end p 18
###begin title 19
VKORC1 sequence variants
###end title 19
###begin p 20
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 187 191 <span type="species:ncbi:10116">rats</span>
###xml 297 301 <span type="species:ncbi:10116">rats</span>
###xml 429 433 <span type="species:ncbi:10116">rats</span>
Some of the observed nucleotide variants do not result in amino acid substitutions and are supposedly silent mutations. Several of these SNPs (e.g. Ile107Ile, Thr137Thr) were detected in rats from USA, Argentina, Thailand, Indonesia and the Azores but not observed in European, Korean or Japanese rats (Table 1). This may be explained by independent population founder effects. The Ile82Ile variant occurred at high frequency in rats from all continents except Africa. This SNP may, thus, be an ancestral variant or may have arisen several times independently.
###end p 20
###begin p 21
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 438 447 438 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 665 673 665 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 707 735 707 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g. T. rubripes, G. gallus </italic>
###xml 739 750 739 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. gambiae </italic>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 144 148 <span type="species:ncbi:10116">rats</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 581 585 <span type="species:ncbi:10116">rats</span>
###xml 712 723 <span type="species:ncbi:31033">T. rubripes</span>
###xml 725 734 <span type="species:ncbi:9031">G. gallus</span>
###xml 739 749 <span type="species:ncbi:7165">A. gambiae</span>
###xml 929 932 <span type="species:ncbi:10116">rat</span>
Of the variants which do cause amino acid substitutions, isoleucine-90 was found to be substituted by leucine and alanine-143 by valine in some rats from both North and South America and/or Southeast Asia. However, in the human VKORC1 protein these latter amino acids represent the wild-type (Fig. 3). Further, they are functionally conservative amino acid substitutions and show similar or even higher VKOR activities than the wild-type in vitro (Fig. 1). Thus, these substitutions can be considered functionally neutral variants. Isoleucine-141 was substituted by valine in some rats from Indonesia. It reduces VKOR activity to the half of the wild-type activity in vitro. In the VKORC1 of other species, e.g. T. rubripes, G. gallus and A. gambiae (Fig. 3) valine represents the wild-type at position 141. The effect of the Ile141Val mutation in combination with the change from alanine-143 to valine which was observed in one rat from Indonesia remains to be investigated.
###end p 21
###begin p 22
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alignment of VKORC1 proteins of different species</bold>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 116 120 <span type="species:ncbi:10116">rats</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
Alignment of VKORC1 proteins of different species. Amino acid substitutions which could be detected in the examined rats and mice are highlighted by grey shading. Black boxes indicate the predicted transmembrane domains (according to the topology model of Tie et al., 2005 [30]). Blue shaded amino acid residues refer to the CXXC motif which is supposed to be the active site of the VKORC1 protein. The TYA motif which is highlighted in pink is the proposed warfarin binding site [25].
###end p 22
###begin p 23
###xml 95 104 95 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 300 305 <span type="species:ncbi:9606">human</span>
###xml 554 560 <span type="species:ncbi:10090">murine</span>
###xml 639 645 <span type="species:ncbi:10090">murine</span>
Other amino acid substitutions were shown to only have a slight effect on VKOR activity in the in vitro assay. The glutamate residue at position 37 was found to be substituted by glycine in 12 mice from Berlin, Germany. This glutamate is not highly conserved, not even in other vertebrates, e.g. the human VKORC1 has an arginine at this position (Fig. 3). VKOR activity assays of the Gly37 variant revealed a basal VKOR activity of 75% compared to the wild-type protein. The Gly37 variant is inhibited by warfarin in a manner comparable to the wild-type murine VKORC1 protein (Fig. 2). Thus, Gly37 rather seems to be a polymorphism in the murine VKORC1 with only a minor effect on protein function.
###end p 23
###begin title 24
VKORC1 mutations
###end title 24
###begin p 25
###xml 516 517 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 8 12 <span type="species:ncbi:10116">rats</span>
###xml 131 135 <span type="species:ncbi:10116">rats</span>
###xml 215 219 <span type="species:ncbi:10116">rats</span>
###xml 294 298 <span type="species:ncbi:10116">rats</span>
###xml 364 368 <span type="species:ncbi:10116">rats</span>
###xml 565 569 <span type="species:ncbi:10116">rats</span>
###xml 750 754 <span type="species:ncbi:10116">rats</span>
###xml 785 789 <span type="species:ncbi:10116">rats</span>
English rats showed the greatest diversity of mutations in the VKORC1 gene. Three already described mutations could be detected in rats trapped in different English counties: the Tyr139Cys substitution was found in rats from Gloucestershire, Norfolk and Lincolnshire, the Tyr139Ser mutation in rats from Shropshire and the Leu128Gln substitution could be shown in rats from Lancashire. All three mutations confer a moderately reduced VKOR activity and are resistant to warfarin inhibition to a variable degree (Fig. 2 and [14]). In two confirmed warfarin-resistant rats from Nottinghamshire an Arg33Pro substitution was observed. VKOR activity of the Arg33Pro variant was reduced to 42% of wild-type activity. A Phe63Cys substitution was detected in rats from Cambridge, including two rats with an additional heterozygous point mutation leading to either an Ala26Thr or a Tyr39Asn amino acid exchange. While Ala26Thr has - similar to Ala26Ser - only a moderate effect on VKOR activity with a reduction to approximately 56% of wild-type activity, the Phe63Cys and the Tyr39Asn substitutions reduce the VKOR activity to about 30% of normal. Since both amino acids Phe63 and Tyr39 are highly conserved in vertebrates and also in the mosquito, a substitution of these amino acids is expected to have an influence on protein function.
###end p 25
###begin p 26
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 68 72 <span type="species:ncbi:10116">rats</span>
VKOR activity measurements of the Glu67Lys variant (observed in six rats from Japan) showed a reduced vitamin K epoxide turnover of about 33% compared to the wild-type protein. However, none of these novel mutations seems to have an effect on warfarin sensitivity in vitro.
###end p 26
###begin p 27
###xml 242 250 242 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 598 606 598 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1239 1241 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 333 337 <span type="species:ncbi:10116">rats</span>
###xml 478 482 <span type="species:ncbi:10116">rats</span>
###xml 850 854 <span type="species:ncbi:10116">rats</span>
###xml 1051 1055 <span type="species:ncbi:10116">rats</span>
The most drastic effect on VKOR activity was observed for the Trp59Arg substitution. Only 16% residual VKOR activity could be measured after recombinant expression of this VKORC1 mutant. Therefore, warfarin resistance could not be tested for in vitro. The Trp59Arg mutation was found both in heterozygous and homozygous genotypes in rats from Argentinean poultry farms. Anticoagulants have been intensively used in these agricultural areas for rodent pest control. In contrast, rats trapped on a waste deposit in Buenos Aires showed no amino acid substitutions in the VKORC1 protein. Given the low in vitro-activity of the Trp59Arg substitution, one could expect animals homozygous for this mutation to suffer from a deficiency of vitamin K-dependent coagulation factors with an increased bleeding risk even without warfarin uptake. In theory, these rats could be rescued by a much higher vitamin K intake as has been described for some warfarin resistant laboratory strains [15-17]. Field investigations of the relative fitness of warfarin-resistant rats on a farm in Shropshire (UK) showed that when selection pressure from anticoagulant use was removed, the frequency of the warfarin resistance gene fell from 80 to 33% over 18 months [18].
###end p 27
###begin p 28
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 507 508 507 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 600 607 <span type="species:ncbi:9031">chicken</span>
Seven mice trapped in Munsterland, Germany, carried the same 5 amino acid substitutions each (Table 2), thus posing the question which conferred warfarin resistance in vivo, either independently or in combination. Recombinant VKOR activities of the variants Ala26Ser and Ala48Thr - when studied separately - were determined at 67% and 118% of normal, respectively. While Ala26 is conserved in most vertebrates, there is a serine at this position in the fruitfly and a threonine in the mosquito VKORC1 (Fig. 3). Similarly, Ala48 is only conserved in higher vertebrates and is substituted by serine in chicken or by arginine in the mosquito (Fig. 3).
###end p 28
###begin p 29
###xml 359 368 359 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 816 824 816 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 853 862 853 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1174 1175 1174 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 582 589 <span type="species:ncbi:9606">patient</span>
###xml 622 629 <span type="species:ncbi:9606">patient</span>
###xml 808 815 <span type="species:ncbi:9606">patient</span>
###xml 927 931 <span type="species:ncbi:10090">mice</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1144 1149 <span type="species:ncbi:10090">mouse</span>
###xml 1296 1300 <span type="species:ncbi:10090">mice</span>
Expression of the variants Arg12Trp, Arg58Gly and Arg61Leu revealed a strong influence on vitamin K epoxide reduction compared to the wild-type protein. All three substitutions reduced VKOR activity to 33%, 39% and 49% of the mouse wild-type, respectively. However, none of these substitutions on their own, conferred a significant warfarin resistance in the in vitro assay (Fig. 2). The Arg58Gly substitution was also found as the only variant - either heterozygous or homozygous - in a total of 13 mice from Germany. The same mutation was described before in a warfarin-resistant patient from Norway (Table 3) [3]. This patient required a weekly dose of 220-250 mg warfarin for an effective anticoagulation therapy (normal dose: 10-60 mg per week). Although warfarin resistance is clearly evident for this patient in vivo it could not be demonstrated in vitro for the Arg58Gly variant nor for the other mutations detected in mice, except for the Tyr139Cys mutation found in wild mice from the Rhineland, Germany and from Terceira, Azores. This mutation has previously been found in anticoagulant-resistant breeding colonies derived from wild mouse populations in England [3,14]. These findings suggests a wide distribution and some selective advantage for this resistance-mediating mutation in mice.
###end p 29
###begin p 30
###xml 41 45 <span type="species:ncbi:10116">rats</span>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 56 62 <span type="species:ncbi:9606">humans</span>
Overview of mutations found in VKORC1 in rats, mice and humans.
###end p 30
###begin p 31
###xml 58 62 <span type="species:ncbi:10116">rats</span>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 94 100 <span type="species:ncbi:9606">humans</span>
###xml 147 151 <span type="species:ncbi:10116">rats</span>
Mutations in bold indicate where resistance was proven in rats or mice, or dosing problems in humans were reported. All sequence variants found in rats were submitted to dbSNP at NCBI  and are indicated by their distinct NCBI_ss# numbers.
###end p 31
###begin p 32
###xml 7 16 7 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 530 534 <span type="species:ncbi:10116">rats</span>
###xml 918 933 <span type="species:ncbi:10116">laboratory rats</span>
###xml 1167 1172 <span type="species:ncbi:10090">mouse</span>
###xml 1319 1323 <span type="species:ncbi:10090">mice</span>
In the in vitro assay used to measure VKOR activity, surprisingly most mutations were rather sensitive to inhibition by warfarin. In the assay used, transfected cells are lysed with relatively high concentrations of detergent (0.5% CHAPS) and, thus, the hydrophobic membrane environment that is required for VKOR activity [19] may have been impaired. These results are, however, consistent with earlier studies on VKOR activity in liver microsomal preparations from Scottish [20,21] and Chicago [22] warfarin-resistant strains of rats that have now been shown to be homozygous for the Leu128Gln and Arg35Pro substitutions, respectively, in VKORC1 [14]. Those studies used intact liver microsomal preparations to determine the kinetic parameters of VKOR activity and its sensitivity to warfarin inhibition. In both resistant strains, the enzyme parameters were found to be very similar to those of warfarin-susceptible laboratory rats. There was evidence, however, that warfarin was less tightly bound to the microsomal preparations from resistant strains and inhibition of VKOR was reversible [21,22]. Similar work on hepatic microsomal preparations from a resistant mouse strain - now known to carry a Leu128Ser substitution in VKORC1 [14] - showed the same activity and warfarin sensitivity of VKOR as in susceptible mice [23].
###end p 32
###begin p 33
###xml 8 17 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo- </italic>
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro-</italic>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1178 1179 1177 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1399 1401 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 183 187 <span type="species:ncbi:10116">rats</span>
###xml 240 244 <span type="species:ncbi:10116">rats</span>
###xml 272 276 <span type="species:ncbi:10116">rats</span>
###xml 360 364 <span type="species:ncbi:10116">rats</span>
###xml 496 500 <span type="species:ncbi:10116">rats</span>
###xml 567 571 <span type="species:ncbi:10116">rats</span>
###xml 742 746 <span type="species:ncbi:10116">rats</span>
###xml 817 821 <span type="species:ncbi:10116">rats</span>
###xml 1052 1055 <span type="species:ncbi:10116">rat</span>
###xml 1193 1197 <span type="species:ncbi:10116">rats</span>
So far, in vivo- and in vitro-data on warfarin resistance match only for substitutions at amino acid position 139 of the VKORC1 protein. Tyr139Cys was identified in this study in two rats from Hungary as well as in five wild-caught English rats and was reported before in rats from Germany (Munsterland), Denmark and from England [14]. In this earlier report, rats were characterized as warfarin-resistant by the blood clotting response test (BCR). The mutation Tyr139Phe was found in six Korean rats in this study, and had been detected before in French and Belgian rats [14]. Warfarin has been extensively used and supplied free of charge to the citizens in Korea since the 1950's. The Tyr139Ser substitution which could be detected in two rats from Shropshire, England had been described in a laboratory strain of rats derived from wild animals trapped in the same area 30 years before [24]. In the recombinant expression system, basal VKOR activities of the Tyr139Cys, the Tyr139Phe and the Tyr139Ser variants, respectively, were lower than of the rat wild-type protein but in the presence of 60 muM warfarin a significantly higher residual VKOR activity was retained (Fig. 1). Therefore, rats bearing either of the Tyr139 mutations should have an enormous selective advantage in warfarin-exposed areas. We have speculated earlier that Tyr139 may be part of the warfarin binding site of VKORC1 [25].
###end p 33
###begin p 34
###xml 43 44 43 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 376 384 376 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 749 757 749 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 856 865 856 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 980 988 980 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 642 647 <span type="species:ncbi:9606">human</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
The synopsis of mutations in VKORC1 (Table 3) shows that amino acid substitutions are observed all over the gene with foci on positions 29 to 48 in exon 1, positions 58 to 67 in exon 2, and 120 to 143 in exon 3. The substitutions Arg33Pro, Arg35Pro, Trp59Arg, Leu120Gln, Leu128Gln, Leu128Ser, Tyr139Cys, Tyr139Phe and Tyr139Ser have been associated with positive results from in vivo resistance testing (by blood clotting response or no-choice feeding tests) in rodents; the replacements Val29Leu, Val45Ala, Arg58Gly, Val66Met and Leu128Arg have been correlated with an increased coumarin requirement for maintaining normal clotting times in human thrombophilic patients. These changes in the VKORC1 protein could, therefore, be associated with the in vivo warfarin resistance phenotype. For amino acid substitutions of Tyr139, this can be followed by the in vitro resistance of recombinant VKORC1 activity to warfarin (Fig. 1). For the remaining substitutions, their relation to in vivo resistance remains to be demonstrated.
###end p 34
###begin title 35
Conclusion
###end title 35
###begin p 36
###xml 143 150 143 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VKORC1 </italic>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 163 167 <span type="species:ncbi:10116">rats</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 689 703 <span type="species:ncbi:10116">laboratory rat</span>
###xml 807 811 <span type="species:ncbi:10116">rats</span>
In conclusion, we have identified 18 novel amino acid substitutions and five known mutations, as well as eight silent sequence variants in the VKORC1 gene of wild rats and mice trapped in anticoagulant-exposed areas on four continents. Although not all of these rodents were classified as warfarin-resistant by BCR or laboratory feeding tests, most of them had survived in an anticoagulant-treated habitat. In a recombinant expression system, VKOR activity was substantially reduced by most VKORC1 variants compared to the wild-type proteins but reduced sensitivity to warfarin inhibition could not be demonstrated in this assay except for the Tyr139 variants. In the Welsh-type resistant laboratory rat strain carrying the Tyr139Ser substitution, low VKOR activity (25-50% in comparison to the susceptible rats) was found to be associated with an enhanced (> 10-fold) dietary vitamin K requirement [17]. It is not known whether a similar dietary compensation would be possible in the wild. Further studies are needed to establish the mechanism by which mutations in the VKORC1 gene lead to warfarin resistance.
###end p 36
###begin title 37
Methods
###end title 37
###begin title 38
Animals
###end title 38
###begin p 39
###xml 11 28 11 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 5 9 <span type="species:ncbi:10116">rats</span>
###xml 11 28 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 201 205 <span type="species:ncbi:10116">Rats</span>
###xml 387 391 <span type="species:ncbi:10116">rats</span>
Wild rats (Rattus norvegicus) were trapped in known or suspected resistance areas in Hungary, England, Indonesia, Korea, Japan, Thailand, South Africa, the USA, Argentina and one island of the Azores. Rats from Chicago, Illinois came from a breeding colony at Genesis Laboratories, Colorado. The founder population of this breeding colony had been acquired in July 2000 by live-trapping rats in Chicago [26]. Three past GLP studies at Genesis Laboratories have identified about half of the animals from the same location in Chicago to be resistant to warfarin by feeding tests [27].
###end p 39
###begin p 40
###xml 11 23 11 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus musculus</italic>
###xml 5 9 <span type="species:ncbi:10090">mice</span>
###xml 11 23 <span type="species:ncbi:10090">Mus musculus</span>
Wild mice (Mus musculus) came from four areas of Germany (Lower Saxony, Berlin, Westphalia and Rhineland) and from the island of Terceira, Azores.
###end p 40
###begin p 41
###xml 70 73 <span type="species:ncbi:10116">rat</span>
###xml 187 191 <span type="species:ncbi:10116">rats</span>
Samples were collected from 2005 through 2007, except for the English rat samples from Gloucestershire, Lancashire, Lincolnshire, Norfolk, Nottinghamshire and Shropshire, which were from rats trapped in 1994 through 1996 and stored frozen.
###end p 41
###begin p 42
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
DNA was extracted from different tissues using standard procedures. The warfarin resistance status of the rodents had been checked in a few cases using blood clotting response [13] or feeding tests [27], but was unknown in most cases.
###end p 42
###begin p 43
All sampling was done under licence and authorization of the regional rodent pest control authorities in accordance with national legislation.
###end p 43
###begin title 44
ARMS-PCR and sequence analysis
###end title 44
###begin p 45
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 176 180 <span type="species:ncbi:10116">rats</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
After DNA extraction, all samples were tested by an allele-specific PCR (ARMS) for the presence of the Tyr139Cys mutation which is the prevalent mutation in warfarin resistant rats and mice from North-Western Europe [14].
###end p 45
###begin p 46
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Samples which were negative in the ARMS test or showed an abnormal band pattern (divergent from the Tyr139Cys band pattern) were sequenced for the three exons of the VKORC1 gene on an automatic sequencer CEQ8000, Beckman Coulter. Primer sequences are available on request and conditions are as described by Pelz et al., 2005 [14].
###end p 46
###begin title 47
Cloning and mutagenesis
###end title 47
###begin p 48
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Rat and mouse VKORC1 cDNAs were cloned into the pCEP4 vector (Invitrogen, Carlsbad, California) and a N-terminal FLAG tag (M-DYKDDDDK) was added to the construct for monitoring of the transfection efficiency by Western blot analysis. Mutations were introduced into the pCEP4-VKORC1 construct with the QuikChange mutagenesis kit (Stratagene, Amsterdam, NL) according to the manufacturer's instructions.
###end p 48
###begin title 49
Expression and VKOR activity assay
###end title 49
###begin p 50
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 34 37 <span type="species:ncbi:10116">rat</span>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
For the recombinant expression of rat and mouse VKORC1 variants HEK293-EBNA cells (Invitrogen, Karlsruhe, Germany) were used as described earlier [25]. The VKOR enzymatic activity of the various VKORC1 proteins was measured in whole-cell extracts before and after addition of different warfarin concentrations as described by Rost et al., 2005 [25]. Aliquots of whole-cell protein extracts were separated on 4-12% NuPAGE gels (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions and blotted onto nitrocellulose membranes (Whatman Schleicher & Schuell, Dassel, Germany). Monoclonal FLAG M2 antibody (Sigma-Aldrich) was used for immuno-staining of the Western blots.
###end p 50
###begin title 51
Authors' contributions
###end title 51
###begin p 52
###xml 177 180 <span type="species:ncbi:10116">rat</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10116">rats</span>
###xml 425 428 <span type="species:ncbi:10116">rat</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
SR performed the mutation screening and cloning, coordinated the VKOR activity studies and drafted the manuscript. HJP conceived of the study, coordinated the collection of all rat and mice samples and the performance of the ARMS test and helped to draft the manuscript. SM carried out the mutagenesis and VKOR activity assays. ADM carried out the resistance-testing of the UK-rats and ADM, VL, KJS and TJ collected numerous rat and mouse samples in their countries and participated in the design of the study. JO and CRM contributed substantially to the conception and design of the study, to the interpretation of data and revised the manuscript. All authors read and approved the final manuscript.
###end p 52
###begin title 53
Acknowledgements
###end title 53
###begin p 54
###xml 68 71 <span type="species:ncbi:10116">rat</span>
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
###xml 134 141 <span type="species:ncbi:9606">persons</span>
The authors gratefully acknowledge the contribution or mediation of rat and mouse tissue samples for VKORC1 analysis by the following persons: Bansch GmbH (Wesseling, Germany), Dr. Daniel Bajomi (Babolna Bio Ltd., Budapest, Hungary), Martin Buske (Umweltbundesamt, Berlin, Germany), Dr. Geoffrey W. Butcher (Babraham Institute, Cambridge, U.K.), Dr. Sandra Essbauer (Bundeswehr Institute of Microbiology, Munich, Germany, Ulrich Kohler (Terceira, Acores), Richard Kruszewski (Biotec-Klute GmbH, Borchen, Germany), Dr. Dorothee Ledbetter (Santa Cruz, CA, USA), Dr. Jeff N. Borchert and Dr. Jeff J. Mach (Genesis Laboratories Inc., Wellington, CO, USA), Kevin R. Porter (Naval Medical Research Center, Silver Spring, MD, USA/Indonesia), Dr. Peter John Taylor (Durban Natural Science Museum, South Africa), Dr. Rainer Ulrich (Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany), Susana Widjaja (U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia), Kumiko Yoshimatsu (Institute for Animal Experimentation, Hokkaido University Graduate School of Medicine, Sapporo, Japan).
###end p 54
###begin p 55
In addition the authors thank Dagmar Funck (Julius Kuehn-Institute, Muenster, Germany) for technical assistance and lab analysis.
###end p 55
###begin article-title 56
Mechanism of warfarin resistance. Warfarin and the metabolism of vitamin K 1
###end article-title 56
###begin article-title 57
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Biochemical basis of hereditary resistance to warfarin in the rat
###end article-title 57
###begin article-title 58
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
###end article-title 58
###begin article-title 59
Identification of the gene for vitamin K epoxide reductase
###end article-title 59
###begin article-title 60
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Vitamin K-dependent carboxylase. Requirements of the rat liver microsomal enzyme system
###end article-title 60
###begin article-title 61
Physiological importance of extra-hepatic vitamin K-dependent carboxylation reactions
###end article-title 61
###begin article-title 62
Vitamin K: the coagulation vitamin that became omnipotent
###end article-title 62
###begin article-title 63
###xml 31 49 31 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 31 48 <span type="species:ncbi:10116">Rattus norvegicus</span>
Case of apparent resistance of Rattus norvegicus Berkenhout to anticoagulant poisons
###end article-title 63
###begin article-title 64
###xml 96 106 <span type="species:ncbi:10116">Norway rat</span>
###xml 108 125 <span type="species:ncbi:10116">Rattus norvegicus</span>
The development and use of a test to identify resistance to the anticoagulant difenacoum in the Norway rat (Rattus norvegicus)
###end article-title 64
###begin article-title 65
###xml 81 92 <span type="species:ncbi:10090">house mouse</span>
###xml 94 106 <span type="species:ncbi:10090">Mus musculus</span>
Trials of the anticoagulant rodenticides bromadiolone and difenacoum against the house mouse (Mus musculus L.)
###end article-title 65
###begin article-title 66
Resistance to the second-generation anticoagulant rodenticides
###end article-title 66
###begin article-title 67
###xml 81 96 81 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus domesticus </italic>
###xml 100 117 100 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 81 95 <span type="species:ncbi:10092">Mus domesticus</span>
###xml 100 117 <span type="species:ncbi:10116">Rattus norvegicus</span>
Performance studies with the new anticoagulant rodenticide, flocoumafen, against Mus domesticus and Rattus norvegicus
###end article-title 67
###begin article-title 68
###xml 109 126 109 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 96 107 <span type="species:ncbi:10116">Norway rats</span>
###xml 109 126 <span type="species:ncbi:10116">Rattus norvegicus</span>
Revised methodology for a blood clotting response test for identification of warfarin-resistant Norway rats (Rattus norvegicus)
###end article-title 68
###begin article-title 69
The genetic basis of resistance to anticoagulants in rodents
###end article-title 69
###begin article-title 70
###xml 72 75 <span type="species:ncbi:10116">rat</span>
Warfarin metabolism and vitamin K requirement in the warfarin-resistant rat
###end article-title 70
###begin article-title 71
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Warfarin resistance and vitamin K requirement in the rat
###end article-title 71
###begin article-title 72
###xml 73 82 <span type="species:ncbi:10116">brown rat</span>
Warfarin resistance: biochemical evaluation of a warfarin-resistant wild brown rat
###end article-title 72
###begin article-title 73
###xml 76 94 76 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus </italic>
###xml 76 93 <span type="species:ncbi:10116">Rattus norvegicus</span>
The population dynamics of genetically determined resistance to warfarin in Rattus norvegicus from mid-Wales
###end article-title 73
###begin article-title 74
Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane
###end article-title 74
###begin article-title 75
###xml 97 101 <span type="species:ncbi:10116">rats</span>
A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats
###end article-title 75
###begin article-title 76
Warfarin resistance. Vitamin K epoxide reductase of Scottish resistance genes is not irreversibly blocked by warfarin
###end article-title 76
###begin article-title 77
###xml 43 47 <span type="species:ncbi:10116">rats</span>
Warfarin resistance in a Chicago strain of rats
###end article-title 77
###begin article-title 78
###xml 118 132 118 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mus domesticus</italic>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 118 132 <span type="species:ncbi:10092">Mus domesticus</span>
Warfarin inhibition of hepatic vitamin K epoxide reductase activity in warfarin-susceptible and resistant house mice (Mus domesticus)
###end article-title 78
###begin article-title 79
###xml 36 40 <span type="species:ncbi:10116">rats</span>
Heritable resistance to warfarin in rats
###end article-title 79
###begin article-title 80
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1
###end article-title 80
###begin article-title 81
###xml 59 70 <span type="species:ncbi:10116">Norway rats</span>
###xml 129 140 <span type="species:ncbi:10116">Norway rats</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Investigations of commensal rodenticide baits against wild Norway rats plus additional toxicology data of warfarin on laboratory Norway rats and house mice
###end article-title 81
###begin article-title 82
Instructions for determining the susceptibility or resistance of rodents to anticoagulant rodenticides
###end article-title 82
###begin article-title 83
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
###end article-title 83
###begin article-title 84
###xml 42 46 <span type="species:ncbi:10116">rats</span>
Warfarin resistance in a French strain of rats
###end article-title 84
###begin article-title 85
Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation
###end article-title 85

